Please login to the form below

Not currently logged in
Email:
Password:

haemophilia

This page shows the latest haemophilia news and features for those working in and with pharma, biotech and healthcare.

Sanofi appoints ex-Roche Reed as new R&D head

Sanofi appoints ex-Roche Reed as new R&D head

The Paris-headquartered firm also secured two major acquisitions in January, buying US haemophilia specialist Bioverativ for $11.6 billion and Belgium’s next-generation biologics firm Ablynx for 3.9

Latest news

More from news
Approximately 45 fully matching, plus 115 partially matching documents found.

Latest Intelligence

  • Health on instalment Health on instalment

    years. Initial disease targets include cancer, neuromuscular disease, haemophilia, immunodeficiencies and blindness.

  • Deal Watch January 2018

    Strategically caplacizumab represented a good fit for Novo Nordisk as it complements the company's portfolio of products focused on haemophilia. ... Portfolio/pipeline in haemophilia and other rare blood disorders. Acquisition company. 11, 600.

  • The good, the bad and the ugly The good, the bad and the ugly

    However, investors fear that challenges in the $11bn haemophilia market could lead to a slump in the haemophilia business it inherited through the Baxalta purchase.

  • Exploring serious market access roadblocks for rare bleeding disorders Exploring serious market access roadblocks for rare bleeding disorders

    This problem is particularly evident in emerging countries. We don’t quite know the scope of the problem, but what is clear is that with conditions such as haemophilia, 75% of ... In addition, epidemiological data can be found from the World Federation

  • Attracting doctors to low-demand specialties Attracting doctors to low-demand specialties

    Haemophilia. One of the specialties in which Porterhouse has worked for many years is haemophilia, a disease that finds itself in a somewhat anomalous position. ... such as leukaemias, lymphomas and myelomas, while haemophilia warrants just one or two

More from intelligence
Approximately 1 fully matching, plus 14 partially matching documents found.

Latest appointments

  • Sobi appoints Torbjorn Hallberg as general counsel Sobi appoints Torbjorn Hallberg as general counsel

    Also sitting on the new team are Sobi's head of specialty care Norbert Oppitz, h ead of medical and scientific affairs Armin Reininger, h ead of haemophilia Philip Wood and

  • Anne Prener to lead Freeline Therapeutics Anne Prener to lead Freeline Therapeutics

    Freeline comprises some of the world’s leading experts in gene therapy, haemophilia and other debilitating disorders and I look forward to working closely with them to demonstrate the potential of ... She has also worked at Novo Nordisk as senir vice

  • Clark Health Communications expands team Clark Health Communications expands team

    Campbell will support and assist the team across its women’s health, gastroenterology and haemophilia accounts.

  • Shire’s Dr Armin Reininger moves to Sobi Shire’s Dr Armin Reininger moves to Sobi

    global medical affairs for haemophilia. ... Armin will apply his deep experience as an industry leader and academic in haemophilia to our team, as well as his global experience in medical scientific affairs to our stakeholders.”.

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 4 fully matching, plus 18 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics